Healthcare
MindMaze Therapeutics Holding S.A.(RLFTF)
Live Price
Offline$0.291
-13.13% today
1Y Change
-89.56%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +39.5%
- EPS Growth
- +83.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MindMaze Therapeutics Holding S.A. (RLFTF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.29 and down 89.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +39.5%, EPS growth of +83.6%, a dividend yield of 0.0%. What stands out right now is revenue +39.5%, EPS +83.6%, free cash flow +82.9% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLFTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+39.5% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 8, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +39.5% and EPS at +83.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 8, 2026 | โ | -7.2% | +2.7% | +24.6% |
2025 Sep 1, 2025 | โ | +5.6% | +9.2% | +27.7% |
2025 Apr 10, 2025 | โ | -0.6% | +0.5% | +1.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLFTF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RLFTF Max Drawdown
-93.53%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RLFTF and SPY.
Company Overview
MindMaze Therapeutics Holding S.A.
Other OTC
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
- Leadership
- Zach W. Henderson
- IPO Date
- Jan 8, 2021
- Employees
- 31
- Street Address
- Chemin de Roseneck 5
- Mailing
- Lausanne, 1202
- Region
- Lausanne, CH
- Reporting Currency
- USD
- Investor Line
- 41 21 552 08 01
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- +39.5%
- EPS
- +83.6%
- Free Cash Flow
- +82.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.